Archive for October, 2003
Why Merck Missed the Mark
Why Merck Missed the Mark
S&P’s Herman Saftlas talks about the Street’s reaction to the drug giant’s disappointing earnings report and what the future may hold
Biotech: Teva’s Next Triumph?
Biotech: Teva’s Next Triumph?
The Israeli maker of generics wants a piece of the fast-growing bio-drug market
Gene Therapy Rebuilds Gums
Gene Therapy Rebuilds Gums
Gene therapy can restore damage caused by severe gum disease, suggest animal studies.
Is Viagra Vulnerable?
Is Viagra Vulnerable?
Eli Lilly’s Cialis lasts for 36 hours–and a $100 million ad blitz will spread the word
It’s Wake-Up Time
It’s Wake-Up Time
Kiss your pillow good-bye. A new breed of drugs promises to do for drowsiness what Prozac did for depression.
Biotech plans: Boon or fantasy?
Biotech plans: Boon or fantasy?
Having mapped hormones, synthesized molecules and discovered new cell receptors, the Scripps Research Institute wants to embark on one of its biggest cloning experiments: converting the Sunshine State into biotech beach by using $510 million from taxpayers.
